Year All20262025202420232022202120202019 April 19, 2022 atai Life Sciences to Participate in Upcoming April Investor Conference April 5, 2022 Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of Second Innovative Formulation of 5-MeO-DMT March 30, 2022 atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform March 23, 2022 atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update March 21, 2022 atai Life Sciences to Participate in Upcoming March Investor Conferences February 16, 2022 atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine February 15, 2022 atai Life Sciences to Participate in Upcoming February Investor Conference January 27, 2022 atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments January 12, 2022 atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program January 10, 2022 atai Life Sciences to Participate in Upcoming January Investor Conference
April 5, 2022 Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of Second Innovative Formulation of 5-MeO-DMT
March 30, 2022 atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform
March 23, 2022 atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
February 16, 2022 atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine
January 27, 2022 atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
January 12, 2022 atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
